Table 1 Clinical trials investigating nanostructures whose endpoint is the treatment of hepatocellular carcinoma
From: Drug delivery strategy in hepatocellular carcinoma therapy
Clinical trial name | Phase | NP type | Loaded drug | NP target | Trial number |
|---|---|---|---|---|---|
ThermoDox study | 3 | Thermally sensitive liposome | Doxorubicin | Stimulus-responsive release | NCT00617981 |
ThermoDox study | 3 | Thermally sensitive liposome | Doxorubicin | Stimulus-responsive release | NCT02112656 |
DCR-MYC study | 1b/2 | Lipid nanoparticle | siRNA Oligonucleotide | Liver targeted gene therapy | NCT02314052 |
Nano Drug Interventional Therapy | 1/2 | Glycyrrhizin mix with gemcitabine | Gemcitabine | Active targeting | NCT02449109 |
PLM60 study | 1 | Liposome | Mitoxantrone hydrochloride | Passive targeting | NCT04331743 |
OPTIMA study | 3 | Thermally sensitive liposome | Doxorubicin | Stimulus-responsive release | NCT02112656 |
ThermoDox study | 1 | Thermally sensitive liposome | Doxorubicin | Stimulus-responsive release | NCT00441376 |
OUTREACH study | 1 | Liposome | Double stranded RNA | Liver targeted gene therapy | NCT02716012 |
L-NDDP study | 1/2 | Liposome | Aroplatin | Passive targeting | NCT00057395 |
TLC D-99 study | 2 | Pegylated liposome | Doxorubicin | Passive targeting | NCT00003296 |
NIFE study | 2 | Liposome | Irinotecan | Passive targeting | NCT03044587 |
ReLive study | 3 | Water insoluble polymer | Doxorubicin | Passive targeting | NCT01655693 |
MRX34 study | 1 | Liposomal mimic | MicroRNA-34a | Liver targeted gene therapy | NCT01829971 |